Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing

Palo Alto Investors LP initiated a new position in Compass Therapeutics (NASDAQ:CMPX), buying 2,532,419 shares during the quarter for a position value of $13,599,090 as of December 31, 2025, according to a February 17, 2026, SEC filing. What Happened According to a SEC filing dated February 17, 2026, Palo Alto Investors LP disclosed the purchase of 2,532,419 shares of Compass Therapeutics in the fourth quarter of 2025. The estimated transaction value was $13.60 million, calculated using the average closi ...